Role of antibiotics for treatment of inflammatory bowel disease

World Journal of Gastroenterology

Volumn 22, Issue 3, 2016, Pages 1078-1087

  Nitzan, Orna ^a   Elias, Mazen ^b,c   Peretz, Avi ^a   Saliba, Walid ^d  

^a BARUCH PADEH MEDICAL CENTER   (Israel)

^b HAEMEK MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

Author keywords

Antibiotic treatment; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CIPROFLOXACIN; METRONIDAZOLE; RIFAMYCIN; RIFAXIMIN; ANTIINFECTIVE AGENT;

ABSCESS; ANTIBIOTIC THERAPY; BACTERIAL COUNT; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; BACTEROIDES; CROHN DISEASE; DIGESTIVE SYSTEM FISTULA; DISEASE ACTIVITY; DISEASE COURSE; ESCHERICHIA COLI; HUMAN; ILEITIS; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MICROBIAL DIVERSITY; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; PRACTICE GUIDELINE; RECURRENT DISEASE; REMISSION; REVIEW; ULCERATIVE COLITIS; ANIMAL; BACTERIUM; COLITIS, ULCERATIVE; DRUG EFFECTS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INTESTINE; MICROBIOLOGY; PATHOGENICITY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL MICROBIOME; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84956544471     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i3.1078     Document Type: Review

References (88)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657 [PMID: 17499606 DOI: 10.1016/S0140-6736(07)60751-X]
2. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]
3. M'Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol 2013; 6: 33-47 [PMID: 24833941 DOI: 10.4137/CGast.S12731]
4. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407 [PMID: 16819502 DOI: 10.1038/ncpgasthep0528]
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429 [PMID: 12167685 DOI: 10.1056/NEJMra020831]
6. Zatorski H, Fichna J. What is the Future of the Gut Microbiota-Related Treatment? Toward Modulation of Microbiota in Preventive and Therapeutic Medicine. Front Med (Lausanne) 2014; 1: 19 [PMID: 25705630 DOI: 10.3389/fmed.2014.00019]
7. Prideaux L, Kang S, Wagner J, Buckley M, Mahar JE, De Cruz P, Wen Z, Chen L, Xia B, van Langenberg DR, Lockett T, Ng SC, Sung JJ, Desmond P, McSweeney C, Morrison M, Kirkwood CD, Kamm MA. Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2906-2918 [PMID: 24240708 DOI: 10.1097/01.MIB.0000435759.05577.12]
8. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, Heath AC, Warner B, Reeder J, Kuczynski J, Caporaso JG, Lozupone CA, Lauber C, Clemente JC, Knights D, Knight R, Gordon JI. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222-227 [PMID: 22699611 DOI: 10.1038/nature11053]
9. de Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 2012; 70 Suppl 1: S45-S56 [PMID: 22861807 DOI: 10.1111/ j.1753-4887.2012.00505.x]
10. Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes 2012; 3: 544-555 [PMID: 23060017 DOI: 10.4161/gmic.22156]
11. Scott KP, Antoine JM, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Health Dis 2015; 26: 25877 [PMID: 25651995 DOI: 10.3402/ mehd.v26.25877]
12. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224-5231 [PMID: 9784526]
13. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-2364 [PMID: 7964509 DOI: 10.1084/jem.180.6.2359]
14. Sartor RB. Does Mycobacteriuavium subspecies paratuberculosis cause Crohn's disease? Gut 2005; 54: 896-898 [PMID: 15951529 DOI: 10.1136/gut.2004.055889]
15. Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Furrer H, Pfyffer GE, Jemmi T, Baumgartner A, Egger M. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: A systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 607-613 [PMID: 17714674 DOI: 10.1016/ S1473-3099(07)70211-6]
16. Kirsner JB. Historical aspects of inflammatory bowel disease. J Clin Gastroenterol 1988; 10: 286-297 [PMID: 2980764 DOI: 10.1097/00004836-198806000-00012]
17. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-693 [PMID: 15082587 DOI: 10.1136/gut.2003.025403]
18. Nishikawa J, Kudo T, Sakata S, Benno Y, Sugiyama T. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand J Gastroenterol 2009; 44: 180-186 [PMID: 18825588 DOI: 10.1080/00365520802433231]
19. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]
20. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421 [PMID: 15300573 DOI: 10.1053/j.gastro.2004.04.061]
21. Boudeau J, Glasser AL, Masseret E, Joly B, Darfeuille-Michaud A. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun 1999; 67: 4499-4509 [PMID: 10456892]
22. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736 [PMID: 18936492 DOI: 10.1073/pnas.0804812105]
23. Midtvedt T, Zabarovsky E, Norin E, Bark J, Gizatullin R, Kashuba V, Ljungqvist O, Zabarovska V, Mollby R, Ernberg I. Increase of faecal tryptic activity relates to changes in the intestinal microbiome: analysis of Crohn's disease with a multidisciplinary platform. PLoS One 2013; 8: e66074 [PMID: 23840402 DOI: 10.1371/journal.pone.0066074]
24. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43: 3380-3389 [PMID: 16000463 DOI: 10.1128/JCM.43.7.3380-3389.2005]
25. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633 [PMID: 15168372 DOI: 10.1053/j.gastro.2004.03.024]
26. Kerman DH, Deshpande AR. Gut microbiota and inflammatory bowel disease: The role of antibiotics in disease management. Postgrad Med 2014; 126: 7-19 [PMID: 25141239 DOI: 10.3810/ pgm.2014.07.2779]
27. Knorr JP, Moshfeghi M, Sokoloski MC. Ciprofloxacin-induced Q-T interval prolongation. Am J Health Syst Pharm 2008; 65: 547-551 [PMID: 18319500 DOI: 10.2146/ajhp070081]
28. Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817; discussion 797 [PMID: 10945507 DOI: 10.1016/S0149-2918(00)80053-3]
29. Sarna JR, Furtado S, Brownell AK. Neurologic complications of metronidazole. Can J Neurol Sci 2013; 40: 768-776 [PMID: 24257215 DOI: 10.1017/S0317167100015870]
30. Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol 2013; 19: 7577-7585 [PMID: 24282348 DOI: 10.3748/wjg.v19.i43.7577]
31. Hashash JG, Binion DG. Managing Clostridium difficile in inflammatory bowel disease (IBD). Curr Gastroenterol Rep 2014; 16: 393 [PMID: 24838421 DOI: 10.1007/s11894-014-0393-1]
32. Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, Shaw S, Van Kruiningen H, Colombel JF, Atreja A. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: A meta-analysis. Am J Gastroenterol 2014; 109: 1728-1738 [PMID: 25223575 DOI: 10.1038/ajg.2014.246]
33. Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011; 60: 49-54 [PMID: 20966024 DOI: 10.1136/gut.2010.219683]
34. Swidsinski A, Loening-Baucke V, Bengmark S, Scholze J, Doerffel Y. Bacterial biofilm suppression with antibiotics for ulcerative and indeterminate colitis: consequences of aggressive treatment. Arch Med Res 2008; 39: 198-204 [PMID: 18164963 DOI: 10.1016/ j.arcmed.2007.08.001]
35. Park SK, Kim KJ, Lee SO, Yang DH, Jung KW, Duk Ye B, Byeon JS, Myung SJ, Yang SK, Kim JH, Sik Yu C. Ciprofloxacin usage and bacterial resistance patterns in Crohn's disease patients with abscesses. J Clin Gastroenterol 2014; 48: 703-707 [PMID: 24296421 DOI: 10.1097/MCG.0000000000000024]
36. Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, Harel J, Simpson KW, Dogan B. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother 2013; 57: 811-817 [PMID: 23183443 DOI: 10.1128/ AAC.02163-12]
37. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-673 [PMID: 21407187 DOI: 10.1038/ajg.2011.72]
38. Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med 2012; 4: 1051-1056 [PMID: 23226773]
39. Su JW, Ma JJ, Zhang HJ. Use of antibiotics in patients with Crohn' s disease: A systematic review and meta-analysis. J Dig Dis 2015; 16: 58-66 [PMID: 25421072 DOI: 10.1111/1751-2980.12216]
40. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15 [PMID: 11837933 DOI: 10.1097/00054725-20 0201000-00002]
41. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR. Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial. Gastroenterology 2002; 123: 33-40 [PMID: 12105831 DOI: 10.1053/gast.2002.34225]
42. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075 [PMID: 1916494 DOI: 10.1136/ gut.32.9.1071]
43. Gugler R, Jensen JC, Schulte H, Vogel R. [The course of Crohn disease and side effect profile with long-term treatment using metronidazole]. Z Gastroenterol 1989; 27: 676-682 [PMID: 2515668]
44. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000; 23: 429-448 [PMID: 11085348 DOI: 10.2165/00002018-200023050-00006]
45. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C. An antibiotic regimen for the treatment of active Crohn' s disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-332 [PMID: 8607501]
46. Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol 2011; 17: 4643-4646 [PMID: 22180705 DOI: 10.3748/wjg.v17.i42.4643]
47. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481.e4 [PMID: 22155172 DOI: 10.1053/j.gastro.2011.11.032]
48. Jigaranu AO, Nedelciuc O, Blaj A, Badea M, Mihai C, Diculescu M, Cijevschi-Prelipcean C. Is rifaximin effective in maintaining remission in Crohn's disease? Dig Dis 2014; 32: 378-383 [PMID: 24969283 DOI: 10.1159/000358141]
49. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95: 725-729 [PMID: 10710065 DOI: 10.1111/ j.1572-0241.2000.01842.x]
50. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D. Twoyear combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-2319 [PMID: 17570206 DOI: 10.1053/j.gastro.2007.03.031]
51. de Groof EJ, Carbonnel F, Buskens CJ, Bemelman WA. Abdominal abscess in Crohn's disease: multidisciplinary management. Dig Dis 2014; 32 Suppl 1: 103-109 [PMID: 25531361 DOI: 10.1159/000367859]
52. Yamaguchi A, Matsui T, Sakurai T, Ueki T, Nakabayashi S, Yao T, Futami K, Arima S, Ono H. The clinical characteristics and outcome of intraabdominal abscess in Crohn's disease. J Gastroenterol 2004; 39: 441-448 [PMID: 15175942 DOI: 10.1007/ s00535-003-1317-2]
53. Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875-880 [PMID: 11910338 DOI: 10.1053/gast.2002.32362]
54. West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers EJ. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: A double-blind placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 1329-1336 [PMID: 15606395 DOI: 10.1111/j.1365-2036.2004.02247.x]
55. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79: 599 [PMID: 7429123]
56. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg 2000; 87: 1697-1701 [PMID: 11122187 DOI: 10.1046/ j.1365-2168.2000.01589.x]
57. Olaison G, Smedh K, Sjödahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 331-335 [PMID: 1568651 DOI: 10.1136/gut.33.3.331]
58. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267 [PMID: 9453485 DOI: 10.1016/S0016-5085(98)70476-7]
59. Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn's disease. World J Gastroenterol 2014; 20: 1147-1154 [PMID: 24574791 DOI: 10.3748/wjg.v20.i5.1147]
60. D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: A controlled randomized trial. Gastroenterology 2008; 135: 1123-1129 [PMID: 18727929 DOI: 10.1053/j.gastro.2008.07.010]
61. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621 [PMID: 7768364 DOI: 10.1016/0016-5085(95)90121-3]
62. Sánchez-Montes C, Ortiz V, Bastida G, Rodríguez E, Yago M, Beltrán B, Aguas M, Iborra M, Garrigues V, Ponce J, Nos P. Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment. World J Gastroenterol 2014; 20: 13999-14003 [PMID: 25320539 DOI: 10.3748/wjg.v20.i38.13999]
63. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22: 31-35 [PMID: 15963077 DOI: 10.1111/ j.1365-2036.2005.02516.x]
64. Tahan S, Melli LC, Mello CS, Rodrigues MS, Bezerra Filho H, de Morais MB. Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. J Pediatr Gastroenterol Nutr 2013; 57: 316-318 [PMID: 23974062 DOI: 10.1097/ MPG.0b013e3182952e93]
65. Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. Curr Med Res Opin 2000; 16: 14-20 [PMID: 16422030 DOI: 10.1185/0300799009117003]
66. Gilat T, Suissa A, Leichtman G, Delpre G, Pavlotzky M, Grossman A, Fireman Z. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 1987; 9: 415-417 [PMID: 2888801 DOI: 10.1097/00004836-198708000-00011]
67. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-1212 [PMID: 3536677 DOI: 10.1136/gut.27.10.1210]
68. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997; 92: 454-456 [PMID: 9068468]
69. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, Triantafyllou G. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36: 971-974 [PMID: 11521989 DOI: 10.1080/00365520120413]
70. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-46 [PMID: 8273796]
71. Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. J Crohns Colitis 2014; 8: 1498-1505 [PMID: 24972748 DOI: 10.1016/j.crohns.2014.06.001]
72. Turunen UM, Färkkilä MA, Hakala K, Seppälä K, Sivonen A, Ogren M, Vuoristo M, Valtonen VV, Miettinen TA. Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-1078 [PMID: 9797360 DOI: 10.1016/ S0016-5085(98)70076-9]
73. Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990; 4: 123-129 [PMID: 2104079 DOI: 10.1111/j.1365-2036.1990.tb00456.x]
74. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220-1221 [PMID: 10389700 DOI: 10.1023/A:1026648812439]
75. Kato K, Ohkusa T, Terao S, Chiba T, Murakami K, Yanaka A, Uehara T, Ishii Y, Soma M, Tajiri H. Adjunct antibiotic combination therapy for steroid-refractory or-dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther 2014; 39: 949-956 [PMID: 24628398 DOI: 10.1111/apt.12688]
76. Gilat T, Leichtman G, Delpre G, Eshchar J, Bar Meir S, Fireman Z. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 1989; 11: 392-395 [PMID: 2569488 DOI: 10.1097/0 0004836-198908000-00008]
77. Lobo AJ, Burke DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther 1993; 7: 155-158 [PMID: 8485268 DOI: 10.1111/ j.1365-2036.1993.tb00084.x]
78. Pardi DS, D'Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis 2009; 15: 1424-1431 [PMID: 19685489 DOI: 10.1002/ibd.21039]
79. Stahlberg D, Gullberg K, Liljeqvist L, Hellers G, Löfberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996; 39: 1012-1018 [PMID: 8797652]
80. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010; (6): CD001176 [PMID: 20556748 DOI: 10.1002/14651858.CD001176. pub2]
81. McLaughlin SD, Clark SK, Shafi S, Petrovska L, Tekkis PP, Ciclitira PJ, Nicholls RJ. Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin Gastroenterol Hepatol 2009; 7: 545-548 [PMID: 19418603 DOI: 10.1016/j.cgh.2009.01.002]
82. Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008; 8: 26 [PMID: 18573211 DOI: 10.1186/1471-230X-8-26]
83. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-483; quiz 464, 484 [PMID: 19174807 DOI: 10.1038/ajg.2008.168]
84. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607 [PMID: 21464096 DOI: 10.1136/gut.2010.224154]
85. Hanauer SB, Sandborn WJ. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut 2007; 56: 161-163 [PMID: 17303600 DOI: 10.1136/gut.2005.089953]
86. Knutson D, Greenberg G, Cronau H. Management of Crohn' s disease-A practical approach. Am Fam Physician 2003; 68: 707-714 [PMID: 12952387]
87. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-523; quiz 524 [PMID: 20068560 DOI: 10.1038/ajg.2009.727]
88. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002]